Search

Your search keyword '"Loken, Michael R."' showing total 6 results
Start Over Author "Loken, Michael R." Journal haematologica
6 results on '"Loken, Michael R."'

1. CD74 is expressed in a subset of pediatric acute myeloid leukemia patients and is a promising target for therapy: a report from the Children’s Oncology Group

Author

Menssen, Andrew J., primary, Hudson, Chad A., additional, Alonzo, Todd, additional, Gerbing, Robert, additional, Pardo, Laura, additional, Leonti, Amanda, additional, Cook, Jacqueline A., additional, Hsu, Fan-Chi, additional, Lott, Loren L., additional, Dai, Fangyan, additional, Fearing, Collette, additional, Ghirardelli, Keely, additional, Hylkema, Tiffany, additional, Tarlock, Katherine, additional, Loeb, Keith R., additional, Kolb, Edward A., additional, Cooper, Todd, additional, Pollard, Jessica, additional, Wells, Denise A., additional, Loken, Michael R., additional, Aplenc, Richard, additional, Meshinchi, Soheil, additional, and Brodersen, Lisa Eidenschink, additional

Published
2024
Full Text
View/download PDF

2. Comprehensive molecular and clinical characterization of NUP98 fusions in pediatric acute myeloid leukemia

Author

Bertrums, Eline J.M., primary, Smith, Jenny L., additional, Harmon, Lauren, additional, Ries, Rhonda E., additional, Wang, Yi-Cheng J., additional, Alonzo, Todd A., additional, Menssen, Andrew J., additional, Chisholm, Karen M., additional, Leonti, Amanda R., additional, Tarlock, Katherine, additional, Ostronoff, Fabiana, additional, Pogosova-Agadjanyan, Era L., additional, Kaspers, Gertjan J.L., additional, Hasle, Henrik, additional, Dworzak, Michael, additional, Walter, Christiane, additional, Muhlegger, Nora, additional, Morerio, Cristina, additional, Pardo, Laura, additional, Hirsch, Betsy, additional, Raimondi, Susana, additional, Cooper, Todd M., additional, Aplenc, Richard, additional, Gamis, Alan S., additional, Kolb, Edward A., additional, Farrar, Jason E., additional, Stirewalt, Derek, additional, Ma, Xiaotu, additional, Shaw, Tim I., additional, Furlan, Scott N., additional, Brodersen, Lisa Eidenschink, additional, Loken, Michael R., additional, Van den Heuvel-Eibrink, Marry M., additional, Zwaan, C. Michel, additional, Triche, Timothy J., additional, Goemans, Bianca F., additional, and Meshinchi, Soheil, additional

Published
2023
Full Text
View/download PDF

3. Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children’s Oncology Group protocol AAML0531

Author

Voigt, Andrew P., primary, Brodersen, Lisa Eidenschink, additional, Alonzo, Todd A., additional, Gerbing, Robert B., additional, Menssen, Andrew J., additional, Wilson, Elisabeth R., additional, Kahwash, Samir, additional, Raimondi, Susana C., additional, Hirsch, Betsy A., additional, Gamis, Alan S., additional, Meshinchi, Soheil, additional, Wells, Denise A., additional, and Loken, Michael R., additional

Published
2017
Full Text
View/download PDF

4. Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group

Author

Westers, Theresia M., primary, Cremers, Eline M.P., additional, Oelschlaegel, Uta, additional, Johansson, Ulrika, additional, Bettelheim, Peter, additional, Matarraz, Sergio, additional, Orfao, Alberto, additional, Moshaver, Bijan, additional, Brodersen, Lisa Eidenschink, additional, Loken, Michael R., additional, Wells, Denise A., additional, Subirá, Dolores, additional, Cullen, Matthew, additional, te Marvelde, Jeroen G., additional, van der Velden, Vincent H.J., additional, Preijers, Frank W.M.B., additional, Chu, Sung-Chao, additional, Feuillard, Jean, additional, Guérin, Estelle, additional, Psarra, Katherina, additional, Porwit, Anna, additional, Saft, Leonie, additional, Ireland, Robin, additional, Milne, Timothy, additional, Béné, Marie C., additional, Witte, Birgit I., additional, Della Porta, Matteo G., additional, Kern, Wolfgang, additional, and van de Loosdrecht, Arjan A., additional

Published
2016
Full Text
View/download PDF

5. Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group.

Author

Westers TM, Cremers EM, Oelschlaegel U, Johansson U, Bettelheim P, Matarraz S, Orfao A, Moshaver B, Brodersen LE, Loken MR, Wells DA, Subirá D, Cullen M, Te Marvelde JG, van der Velden VH, Preijers FW, Chu SC, Feuillard J, Guérin E, Psarra K, Porwit A, Saft L, Ireland R, Milne T, Béné MC, Witte BI, Della Porta MG, Kern W, and van de Loosdrecht AA

Subjects
Adult, Age Factors, Aged, Aged, 80 and over, Biomarkers, Bone Marrow Cells metabolism, Case-Control Studies, Female, Flow Cytometry, Humans, Immunophenotyping, Male, Middle Aged, Young Adult, Erythroid Cells metabolism, Erythroid Cells pathology, Myelodysplastic Syndromes metabolism, Myelodysplastic Syndromes pathology
Abstract

Current recommendations for diagnosing myelodysplastic syndromes endorse flow cytometry as an informative tool. Most flow cytometry protocols focus on the analysis of progenitor cells and the evaluation of the maturing myelomonocytic lineage. However, one of the most frequently observed features of myelodysplastic syndromes is anemia, which may be associated with dyserythropoiesis. Therefore, analysis of changes in flow cytometry features of nucleated erythroid cells may complement current flow cytometry tools. The multicenter study within the IMDSFlow Working Group, reported herein, focused on defining flow cytometry parameters that enable discrimination of dyserythropoiesis associated with myelodysplastic syndromes from non-clonal cytopenias. Data from a learning cohort were compared between myelodysplasia and controls, and results were validated in a separate cohort. The learning cohort comprised 245 myelodysplasia cases, 290 pathological, and 142 normal controls; the validation cohort comprised 129 myelodysplasia cases, 153 pathological, and 49 normal controls. Multivariate logistic regression analysis performed in the learning cohort revealed that analysis of expression of CD36 and CD71 (expressed as coefficient of variation), in combination with CD71 fluorescence intensity and the percentage of CD117 + erythroid progenitors provided the best discrimination between myelodysplastic syndromes and non-clonal cytopenias (specificity 90%; 95% confidence interval: 84-94%). The high specificity of this marker set was confirmed in the validation cohort (92%; 95% confidence interval: 86-97%). This erythroid flow cytometry marker combination may improve the evaluation of cytopenic cases with suspected myelodysplasia, particularly when combined with flow cytometry assessment of the myelomonocytic lineage., (Copyright© Ferrata Storti Foundation.)

Published
2017
Full Text
View/download PDF

6. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes.

Author

van de Loosdrecht AA, Alhan C, Béné MC, Della Porta MG, Dräger AM, Feuillard J, Font P, Germing U, Haase D, Homburg CH, Ireland R, Jansen JH, Kern W, Malcovati L, Te Marvelde JG, Mufti GJ, Ogata K, Orfao A, Ossenkoppele GJ, Porwit A, Preijers FW, Richards SJ, Schuurhuis GJ, Subirá D, Valent P, van der Velden VH, Vyas P, Westra AH, de Witte TM, Wells DA, Loken MR, and Westers TM

Subjects
Antigens, CD immunology, Flow Cytometry standards, Humans, Immunophenotyping methods, Myelodysplastic Syndromes immunology, Reference Standards, Flow Cytometry methods, Myelodysplastic Syndromes diagnosis
Abstract

The myelodysplastic syndromes are a group of clonal hematopoietic stem cell diseases characterized by cytopenia(s), dysplasia in one or more cell lineages and increased risk of evolution to acute myeloid leukemia (AML). Recent advances in immunophenotyping of hematopoietic progenitor and maturing cells in dysplastic bone marrow point to a useful role for multiparameter flow cytometry (FCM) in the diagnosis and prognostication of myelodysplastic syndromes. In March 2008, representatives from 18 European institutes participated in a European LeukemiaNet (ELN) workshop held in Amsterdam as a first step towards standardization of FCM in myelodysplastic syndromes. Consensus was reached regarding standard methods for cell sampling, handling and processing. The group also defined minimal combinations of antibodies to analyze aberrant immunophenotypes and thus dysplasia. Examples are altered numbers of CD34(+) precursors, aberrant expression of markers on myeloblasts, maturing myeloid cells, monocytes or erythroid precursors and the expression of lineage infidelity markers. When applied in practice, aberrant FCM patterns correlate well with morphology, the subclassification of myelodysplastic syndromes, and prognostic scoring systems. However, the group also concluded that despite strong evidence for an impact of FCM in myelodysplastic syndromes, further (prospective) validation of markers and immunophenotypic patterns are required against control patient groups as well as further standardization in multi-center studies. Standardization of FCM in myelodysplastic syndromes may thus contribute to improved diagnosis and prognostication of myelodysplastic syndromes in the future.

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results